Cardiac Septal Occluders - Medical Devices Pipeline Assessment, 2017

  • ID: 4339069
  • Report
  • 98 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Aporo Biomedical, Inc.
  • CARAG AG
  • Celyad SA
  • Cierra, Inc.
  • Dextera Surgical Inc
  • SeptRx, Inc.
  • MORE
Cardiac Septal Occluders - Medical Devices Pipeline Assessment, 2017

Summary

The author's Medical Devices sector report, “Cardiac Septal Occluders - Medical Devices Pipeline Assessment, 2017" provides an overview of Cardiac Septal Occluders currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Septal Occluders pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Cardiac Septal Occluders under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Cardiac Septal Occluders and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Cardiac Septal Occluders under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aporo Biomedical, Inc.
  • CARAG AG
  • Celyad SA
  • Cierra, Inc.
  • Dextera Surgical Inc
  • SeptRx, Inc.
  • MORE
1 Table of Contents
2 Introduction
2.1 Cardiac Septal Occluders Overview
3 Products under Development
3.1 Cardiac Septal Occluders - Pipeline Products by Stage of Development
3.2 Cardiac Septal Occluders - Pipeline Products by Segment
3.3 Cardiac Septal Occluders - Pipeline Products by Territory
3.4 Cardiac Septal Occluders - Pipeline Products by Regulatory Path
3.5 Cardiac Septal Occluders - Pipeline Products by Estimated Approval Date
3.6 Cardiac Septal Occluders - Ongoing Clinical Trials
4 Cardiac Septal Occluders - Pipeline Products under Development by Companies
4.1 Cardiac Septal Occluders Companies - Pipeline Products by Stage of Development
4.2 Cardiac Septal Occluders - Pipeline Products by Stage of Development
5 Cardiac Septal Occluders Companies and Product Overview
5.1 Aporo Biomedical, Inc. (Inactive) Company Overview
5.1.1 Aporo Biomedical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.2 CARAG AG Company Overview
5.2.1 CARAG AG Pipeline Products & Ongoing Clinical Trials Overview
5.3 Celyad SA Company Overview
5.3.1 Celyad SA Pipeline Products & Ongoing Clinical Trials Overview
5.4 Cierra, Inc. (Inactive) Company Overview
5.4.1 Cierra, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.5 CoAptus Medical Corporation Company Overview
5.5.1 CoAptus Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.6 Dextera Surgical Inc Company Overview
5.6.1 Dextera Surgical Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Lifetech Scientific (Shenzhen) Co Ltd Company Overview
5.7.1 Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.8 Micro Interventional Devices, Inc. Company Overview
5.8.1 Micro Interventional Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.9 Occlutech International AB Company Overview
5.9.1 Occlutech International AB Pipeline Products & Ongoing Clinical Trials Overview
5.10 SeptRx, Inc. (Inactive) Company Overview
5.10.1 SeptRx, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.11 St. Jude Medical LLC Company Overview
5.11.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
5.12 Sutura, Inc. (Inactive) Company Overview
5.12.1 Sutura, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.13 Swissimplant AG (Inactive) Company Overview
5.13.1 Swissimplant AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.14 University of Minnesota Company Overview
5.14.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
5.15 Vascular Concepts Ltd Company Overview
5.15.1 Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.16 W. L. Gore & Associates Inc Company Overview
5.16.1 W. L. Gore & Associates Inc Pipeline Products & Ongoing Clinical Trials Overview
6 Cardiac Septal Occluders- Recent Developments
6.1 Jul 03, 2017: Lifetech Announced the Launch of its Global Post-market Surveillance Study for Lambre LAA Closure System
6.2 May 19, 2017: Celyad Announces First Quarter 2017 Business Update
6.3 May 16, 2017: Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure
6.4 May 04, 2017: Dextera Surgical Reports Fiscal 2017 Third Quarter Financial Results
6.5 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results
6.6 Apr 24, 2017: Dextera Surgical Announces Preliminary Fiscal 2017 Third Quarter Financial Highlights
6.7 Apr 05, 2017: Occlutech Obtains European CE Mark for its Novel PmVSD Occluder
6.8 Mar 30, 2017: MPSC Announces 2016 Annual Results
6.9 Mar 24, 2017: LifeTech Announces 2016 Annual Results
6.10 Mar 13, 2017: Cook Medical Announces Umesh Patel as President of Cook Biotech
6.11 Mar 07, 2017: Anteo Technologies Announces Verification Study With Cook Medical Australia
6.12 Feb 08, 2017: Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in Texas to Use AMPLATZER Amulet Left Atrial Appendage Occluder
6.13 Feb 07, 2017: Dextera Surgical Reports Fiscal 2017 Second Quarter Financial Results
6.14 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results
6.15 Dec 13, 2016: Aurora St. Luke’s Medical Center is first hospital in Wisconsin to implant device to close holes in heart
6.16 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
6.17 Nov 18, 2016: Only FDA-Approved Device to Repair Hole in the Heart Condition Now Available at Baylor Heart and Vascular Services at Fort Worth
6.18 Nov 18, 2016: Celyad Announces Third Quarter 2016 Business Update
6.19 Nov 07, 2016: Dextera Surgical Reports Fiscal 2017 First Quarter Financial Results
6.20 Nov 02, 2016: Largest Observational Study to Date of the St. Jude Medical AMPLATZER Amulet Left Atrial Appendage Occluder Demonstrates High Implant Success and Strong Safety Profile
6.21 Nov 01, 2016: St. Jude Medical Welcomes Landmark Stroke Data from the RESPECT Trial
6.22 Nov 01, 2016: Long-Term Study Results Show That PFO Closure is More Effective than Medical Management in Preventing Recurrent Stroke
6.23 Oct 28, 2016: FDA approves new device for prevention of recurrent strokes in certain patients
6.24 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results
6.25 Oct 24, 2016: St. Jude Medical Announces Data to be Presented as Late-Breaking Clinical Trials and Highlights Its Latest Cardiovascular Portfolio at the 2016 TCT Conference
6.26 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results
6.27 Oct 18, 2016: St. Jude Medical, FDA And Top Pediatric Cardiology Experts Announce New Clinical Trial To Treat Congenital Heart Defects
6.28 Sep 19, 2016: Organogenesis Announces New Chief Financial Officer
6.29 Sep 01, 2016: St. Jude Medical Launches Global Clinical Trial to Evaluate a New Therapy Option for Patients at an Increased Risk of Stroke Due to Atrial Fibrillation
6.30 Aug 31, 2016: Cook Medical Names Jean-Marc Creissel Vice President of Operations in Greater China
6.31 Aug 30, 2016: MPSC Announces 2016 Interim Results
6.32 Aug 25, 2016: Celyad Reports First Half 2016 Financial Results and Operational Progress
6.33 Aug 09, 2016: Dextera Surgical Reports FY 2016 Fourth Quarter Financial Results
6.34 Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Cardiac Septal Occluders - Pipeline Products by Stage of Development
Table 2: Cardiac Septal Occluders - Pipeline Products by Segment
Table 3: Cardiac Septal Occluders - Pipeline Products by Territory
Table 4: Cardiac Septal Occluders - Pipeline Products by Regulatory Path
Table 5: Cardiac Septal Occluders - Pipeline Products by Estimated Approval Date
Table 6: Cardiac Septal Occluders - Ongoing Clinical Trials
Table 7: Cardiac Septal Occluders Companies - Pipeline Products by Stage of Development
Table 8: Cardiac Septal Occluders - Pipeline Products by Stage of Development
Table 9: Aporo Biomedical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Patent Foramen Ovale Closure Device - Product Status
Table 11: Patent Foramen Ovale Closure Device - Product Description
Table 12: CARAG AG Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Solysafe Septal Occluder - Degradable Version - Product Status
Table 14: Solysafe Septal Occluder - Degradable Version - Product Description
Table 15: CARAG AG - Ongoing Clinical Trials Overview
Table 16: Solysafe Septal Occluder - Degradable Version - Prospective Single Center Pilot Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device with Biodegradable Framework in Patients with Clinically Significant Atrial Septum Defect (ASD) or Patent Foramen Ovale (PFO)
Table 17: Celyad SA Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Cardiao3 Closure Device - Product Status
Table 19: Cardiao3 Closure Device - Product Description
Table 20: Cierra, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 21: PFx Closure System - Product Status
Table 22: PFx Closure System - Product Description
Table 23: CoAptus Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Non-Implant Therapeutic Catheter Device - Product Status
Table 25: Non-Implant Therapeutic Catheter Device - Product Description
Table 26: Dextera Surgical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: PFO Closure Device - Product Status
Table 28: PFO Closure Device - Product Description
Table 29: Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Absorbable Occluder - Product Status
Table 31: Absorbable Occluder - Product Description
Table 32: IrisFIT PFO Occluder - Product Status
Table 33: IrisFIT PFO Occluder - Product Description
Table 34: LAmbre LAA Closure System - Product Status
Table 35: LAmbre LAA Closure System - Product Description
Table 36: Lifetech Scientific (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
Table 37: LAmbre LAA Closure System - Evaluation of Safety and Efficacy of the New Generation of Left Appendage Closure With the Lambre Device in AF Patients Not Suitable for Use of Warfarin
Table 38: LAmbre LAA Closure System - LifeTech LAmbre Keft Atrial Appendage (LAA) Closure System Post-market Clinical Follow-up
Table 39: LAmbre LAA Closure System - Study of Safety and Efficacy of a Left Atrial Appendage Occulder
Table 40: IrisFIT PFO Occluder - Post Market Clinical Follow-up Study of IrisFIT PFO (Patent Foramen Ovale)
Table 41: Micro Interventional Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 42: Patent Foramen Ovale Fixation Device - Product Status
Table 43: Patent Foramen Ovale Fixation Device - Product Description
Table 44: Occlutech International AB Pipeline Products & Ongoing Clinical Trials Overview
Table 45: mVSD Device - Product Status
Table 46: mVSD Device - Product Description
Table 47: Occlutech Figulla Flex II ASD Occluder - Product Status
Table 48: Occlutech Figulla Flex II ASD Occluder - Product Description
Table 49: Occlutech Figulla Flex II PFO Occluder - Product Status
Table 50: Occlutech Figulla Flex II PFO Occluder - Product Description
Table 51: Occlutech Figulla Flex UNI - Product Status
Table 52: Occlutech Figulla Flex UNI - Product Description
Table 53: Occlutech LAA Occluder - Product Status
Table 54: Occlutech LAA Occluder - Product Description
Table 55: Occlutech PDA Occluder - Product Status
Table 56: Occlutech PDA Occluder - Product Description
Table 57: Occlutech International AB - Ongoing Clinical Trials Overview
Table 58: Occlutech LAA Occluder - Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage in Patients with Atrial Fibrillation
Table 59: Occlutech Figulla Flex II ASD Occluder - International Registry for Secundum Atrial Septal Defects Closure by Using the Occlutech Flex II Device in More than 2000 Patients
Table 60: SeptRx, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 61: SeptRx IPO - Product Status
Table 62: SeptRx IPO - Product Description
Table 63: St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 64: Amplatzer Amulet Left Atrial Appendage Occluder - Product Status
Table 65: Amplatzer Amulet Left Atrial Appendage Occluder - Product Description
Table 66: AMPLATZER Duct Occluder II AS - Product Status
Table 67: AMPLATZER Duct Occluder II AS - Product Description
Table 68: St. Jude Medical LLC - Ongoing Clinical Trials Overview
Table 69: Amplatzer Amulet Left Atrial Appendage Occluder - AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial
Table 70: Amplatzer Amulet Left Atrial Appendage Occluder - Amplatzer Amulet Observational Post-market Study
Table 71: Amplatzer Amulet Left Atrial Appendage Occluder - Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients after Intracerebral Hemorrhage: A Multicenter Randomized Clinical Trial
Table 72: AMPLATZER Duct Occluder II AS - AMPLATZER Duct Occluder II Additional Sizes: ADO II AS Clinical Study
Table 73: Sutura, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 74: HeartStitch - Product Status
Table 75: HeartStitch - Product Description
Table 76: Swissimplant AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Solysafe Septal Occluder - 10Fr Sheath - Product Status
Table 78: Solysafe Septal Occluder - 10Fr Sheath - Product Description
Table 79: University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Bioresorbable Occlusion Device - Product Status
Table 81: Bioresorbable Occlusion Device - Product Description
Table 82: Vascular Concepts Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 83: VSD (Ventricular Septal Device) - Product Status
Table 84: VSD (Ventricular Septal Device) - Product Description
Table 85: W. L. Gore & Associates Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 86: BioTREK - Product Status
Table 87: BioTREK - Product Description
Table 88: GORE CARDIOFORM Septal Occluder - Patent Foramen Ovale - Product Status
Table 89: GORE CARDIOFORM Septal Occluder - Patent Foramen Ovale - Product Description
Table 90: GORE HELEX Septal Occluder - PFO - Product Status
Table 91: GORE HELEX Septal Occluder - PFO - Product Description
Table 92: W. L. Gore & Associates Inc - Ongoing Clinical Trials Overview
Table 93: GORE CARDIOFORM Septal Occluder - Patent Foramen Ovale - GORE CARDIOFORM ASD Occluder Clinical Study: A Study to Evaluate Safety and Efficacy in the Treatment of Transcatheter Closure of Ostium Secundum Atrial Septal Defects (ASDs) - The Gore ASSURED Clinical Study
Table 94: Glossary

List of Figures
Figure 1: Cardiac Septal Occluders - Pipeline Products by Stage of Development
Figure 2: Cardiac Septal Occluders - Pipeline Products by Segment
Figure 3: Cardiac Septal Occluders - Pipeline Products by Territory
Figure 4: Cardiac Septal Occluders - Pipeline Products by Regulatory Path
Figure 5: Cardiac Septal Occluders - Pipeline Products by Estimated Approval Date
Figure 6: Cardiac Septal Occluders - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aporo Biomedical, Inc.
  • CARAG AG
  • Celyad SA
  • Cierra, Inc.
  • CoAptus Medical Corporation
  • Dextera Surgical Inc
  • Lifetech Scientific (Shenzhen) Co Ltd
  • Micro Interventional Devices, Inc.
  • Occlutech International AB
  • SeptRx, Inc.
  • St. Jude Medical LLC
  • Sutura, Inc.
  • Swissimplant AG
  • University of Minnesota
  • Vascular Concepts Ltd
  • W. L. Gore & Associates Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll